reported that the positive rate of SET-CAN/NUP214 fusion gene in 196 patients with T-ALL was about 5.6% (21), in 2022, Yan C and others first reported two CML patients with positive SET-CAN/NUP214 fusion gene (7). This evidence concerns the gene NUP214 and chronic myelogenous leukemia, BCR-ABL1 positive.